Halozyme Therapeutics, Inc. (FRA:RV7)

Market Cap	6.35B
Revenue (ttm)	1.06B
Net Income (ttm)	507.54M
Shares Out	n/a
EPS (ttm)	4.04
PE Ratio	12.51
Forward PE	7.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	224
Average Volume	89
Open	55.16
Previous Close	56.20
Day's Range	54.44 - 55.20
52-Week Range	42.45 - 66.90
Beta	n/a
RSI	36.05
Earnings Date	Feb 18, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 350
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RV7

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD